文献速递胰腺与胆道疾病

帕瑞昔布序贯艾瑞昔布对重症急性胰腺炎发生与缓解的作用:多中心、双盲、随机、安慰剂对照试验

Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Gut · 2025-08-07

本研究为多中心、双盲、随机、安慰剂对照试验,纳入348例急性胰腺炎患者,评估环氧合酶-2抑制剂(帕瑞昔布序贯艾瑞昔布)治疗重症急性胰腺炎(SAP)的疗效与安全性。结果显示,与安慰剂组相比,COX-2抑制剂组SAP发生率降低20.7%(77.6% vs 61.5%,p=0.001),SAP持续器官衰竭时间缩短2天(p<0.001),局部并发症发生率显著降低(33.7% vs 49.1%,p=0.004),30天死亡率从8.6%降至3.4%(p<0.05),不良事件发生率两组相似。

要点

  • COX-2抑制剂组SAP发生率较安慰剂组降低20.7%(77.6% vs 61.5%,p=0.001)。
  • COX-2抑制剂组SAP持续器官衰竭时间较安慰剂组缩短2天(p<0.001)。
  • COX-2抑制剂组局部并发症发生率显著低于安慰剂组(33.7% vs 49.1%,p=0.004)。

核心结论

  • 帕瑞昔布序贯艾瑞昔布通过抑制全身炎症反应,有效且耐受性良好地降低SAP的发生率、持续时间及局部并发症,从而降低发病率。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、研究者发起的试验,纳入348例年龄18-75岁、发病至入院<1周、APACHE II评分≥7或改良Marshall评分≥2的急性胰腺炎患者,按1:1随机分配至COX-2抑制剂组(帕瑞昔布序贯艾瑞昔布)或安慰剂组。

主要发现

  • 与安慰剂组相比,COX-2抑制剂组SAP发生率降低20.7%(77.6% vs 61.5%,p=0.001),SAP持续器官衰竭时间缩短2天(p<0.001)。
  • 症状发作48小时内入组患者中,COX-2抑制剂组SAP发生率降低23.8%(p=0.001),SAP持续器官衰竭时间缩短3天(p=0.001);48小时后入组患者中分别降低8.5%(p=0.202)和缩短2天(p=0.010)。
  • COX-2抑制剂组局部并发症发生率显著低于安慰剂组(33.7% vs 49.1%,p=0.004)。
  • COX-2抑制剂治疗后血清炎症介质水平及30天死亡率(从8.6%降至3.4%)显著降低,p<0.05。
  • 不良事件发生率两组相似。

临床怎么用

  • 作者认为,帕瑞昔布序贯艾瑞昔布可有效且耐受性良好地降低SAP的发生率、持续时间及局部并发症,通过抑制全身炎症反应降低发病率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no effective drug treatment for the organ failure (OF) caused by severe acute pancreatitis (SAP). OBJECTIVE: We aimed to evaluate the efficacy of cyclooxygenase-2 inhibitors (COX-2-Is) on the treatment of SAP and its safety. DESIGN: In this multicentre, double-blind, randomised, placebo-controlled, investigator-initiated trial, 348 patients with acute pancreatitis aged 18-75 years, <1 week from onset of illness to admission, and Acute Physiology and Chronic Health Evaluation II Score ≥7 or modified Marshall Score ≥2, were randomly assigned (1:1) to the COX-2-Is group (parecoxib sequential with imrecoxib) or the placebo group. SAP occurrence, duration of OF, local complications, clinical outcomes and serum inflammatory mediators were measured. RESULTS: Compared with the placebo group, SAP occurrence was reduced by 20.7% (77.6% vs 61.5%, p=0.001) and the persistent OF duration in SAP was shortened by 2 days (p<0.001) after COX-2-Is treatment. For patients enrolled within or after 48 hours from symptom onset, SAP occurrence was reduced by 23.8% (p=0.001) and 8.5% (p=0.202), and the persistent OF duration in SAP was shortened by 3 days (p=0.001) and 2 days (p=0.010) after COX-2-Is treatment, respectively. The occurrence of local complications in the COX-2-Is group was significantly lower than those in the placebo group, 33.7% vs 49.1%, p=0.004. The serum levels of inflammatory mediators and 30-day mortality (from 8.6% to 3.4%) were significantly reduced after COX-2-Is treatment, p<0.05. The incidence of adverse events was similar between the two treatment groups. CONCLUSION: Parecoxib sequential with imrecoxib was effective and well tolerated in reducing the occurrence and duration of SAP and local complications through suppression of systemic inflammatory response, leading to decreased morbidity.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Huang L, Feng Z, Yang W, et al. Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial. Gut. 2025. PMID: 40301118. doi:10.1136/gutjnl-2024-334038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。